<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lymphomatoid papulosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lymphomatoid papulosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Lymphomatoid papulosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marshall E Kadin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John A Zic, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 23, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1563670477"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Lymphomatoid papulosis (LyP) is a recurrent, self-healing papulonodular skin eruption with histologic features of a CD30<sup>+</sup> lymphoid proliferation of atypical T cells [<a href="#rid1">1,2</a>]. LyP is part of the group of cutaneous CD30<sup>+</sup> lymphoproliferative disorders (LPDs) that includes primary cutaneous anaplastic large cell lymphoma (PC-ALCL) and borderline CD30<sup>+</sup> lesions. Clinicopathologic correlation is essential for establishing the diagnosis of LyP, as there are many clinical and histologic mimics of LyP.</p><p>LyP is characterized by a chronic course, lasting years or decades. Grouped or generalized papules and nodules develop and spontaneously regress over weeks to months  (<a class="graphic graphic_picture graphicRef71441" href="/z/d/graphic/71441.html" rel="external">picture 3B</a>). Patients with LyP have an excellent prognosis, although they are at increased risk of developing a second cutaneous or nodal lymphoma, such as mycosis fungoides, PC-ALCL, or Hodgkin lymphoma.</p><p>This topic will discuss the clinical presentation, diagnosis, and treatment of LyP. Other cutaneous T cell lymphomas are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4744.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T cell lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H18325846"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Lymphomatoid papulosis (LyP) is a rare disease. The estimated incidence is 1.2 to 1.9 cases per million persons per year [<a href="#rid3">3</a>]. It occurs in patients of all ethnic groups with a peak incidence in the fifth decade. However, LyP may occur in children and individuals older than 50 years [<a href="#rid4">4-6</a>]. A bimodal distribution by age and sex has been noted, with a male predominance among pediatric cases and a female predominance among adult cases  (<a class="graphic graphic_figure graphicRef82789" href="/z/d/graphic/82789.html" rel="external">figure 1</a>) [<a href="#rid7">7</a>]. Most patients with LyP and 6p25.3 gene rearrangement are older adults [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H18325853"><span class="h1">ETIOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>The cause of lymphomatoid papulosis (LyP) is unknown. The hypothesis of a viral etiology has not been confirmed. In several studies, oncogenic or lymphotropic viruses, including Epstein-Barr virus, herpes viruses 6, 7, and 8, and human T cell leukemia/lymphoma virus were not detected in LyP lesions [<a href="#rid9">9-13</a>]. Atopy may have a role in the pathogenesis of LyP. In a study of 28 patients with LyP and 52 healthy controls, approximately 50 percent of patients with LyP had serologic evidence of atopy compared with 3 percent of controls [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H17871189"><span class="h2">Overexpression of CD30</span><span class="headingEndMark"> — </span>The overexpression of CD30 on the large atypical T cells found in the skin lesions is the hallmark of LyP and primary cutaneous anaplastic large cell lymphoma (PC-ALCL). CD30 is a cell surface cytokine receptor belonging to the tumor necrosis factor (TNF) receptor superfamily 8, first identified on the Reed-Sternberg cells in Hodgkin lymphoma. CD30 is expressed on activated T and B cells but not on mature circulating T or B cells. The interaction of CD30 with its membrane-associated glycoprotein ligand (CD30L) activates the nuclear factor kappa-B (NFkB) signal transduction pathway, resulting in either cell proliferation or apoptosis [<a href="#rid15">15-17</a>].</p><p>The genetic abnormalities underlying the CD30 overexpression in LyP are largely unknown. One study found that two allelic forms of the CD30 promoter microsatellite repressive element, designated 30M377 and 30M362, were associated with the development of LyP and progression to CD30<sup>+</sup> lymphomas in patients with LyP [<a href="#rid18">18</a>]. These findings suggest that allele-specific differences in the control of CD30 transcription may have a role in the pathogenesis of CD30<sup>+</sup> cutaneous lymphoproliferative disorders (LPDs).</p><p class="headingAnchor" id="H17871982"><span class="h2">Clonality of T cells</span><span class="headingEndMark"> — </span>Monoclonal rearrangement of the T cell receptor (<em>TCR</em>) genes has been detected in 40 to 100 percent of the LyP skin lesions [<a href="#rid19">19-23</a>]. (See  <a class="medical medical_review" href="/z/d/html/3950.html" rel="external">"T-B-NK+ SCID: Pathogenesis, clinical manifestations, and diagnosis", section on 'T cell receptor generation'</a>.)</p><p>In patients with LyP and associated lymphoma, identical rearrangements have been identified in LyP lesions and lymphoma cells [<a href="#rid24">24-32</a>]. (See <a class="local">'Associated hematologic malignancies'</a> below.)</p><p>Several studies indicate that the CD30<sup>+</sup> cells are the clonal T cells in LyP [<a href="#rid19">19,24,25,33,34</a>]. However, it is not known whether the clonal T cells persist in the skin or in the peripheral blood during the remission periods [<a href="#rid22">22</a>].</p><p>In an analysis of the <em>TCR</em> gene rearrangements, multiple skin and blood samples were obtained from patients with LyP at the time of active disease and remission [<a href="#rid20">20</a>]. Overall, clonal T cell populations were detected in 78 percent of the skin samples and in 36 percent of blood samples. The direct comparison of the clonal T cell populations detected in the lesional skin and corresponding blood sample of each patient revealed a different rearrangement pattern in all instances. These findings suggest that T cell clones detected in the peripheral blood of patients with LyP are non-neoplastic and represent a reactive response to an unknown antigen.</p><p class="headingAnchor" id="H17871988"><span class="h2">Genetic abnormalities</span><span class="headingEndMark"> — </span>Genetic abnormalities found in LyP by classic cytogenetic studies include aneuploidy and chromosomal aberrations [<a href="#rid10">10,35</a>]. The t(2;5)(p23,q35) translocation characteristic of systemic ALCL has not been found in LyP cells [<a href="#rid36">36</a>]. However, there is immunohistochemical evidence of increased expression in LyP cells of the oncogenic transcription factor gene <em>Fra2</em> and inhibitor of differentiation gene <em>Id2</em>, which are located in close proximity to the t(2;5) breakpoint, suggesting a pathogenetic relationship between LyP and systemic ALCL [<a href="#rid37">37</a>].</p><p>A subset of LyP cases affecting mainly older adult patients has been found to have chromosomal rearrangements involving the DUSP22-IRF4 locus on 6p25.3, a genetic abnormality seen in approximately 28 percent of PC-ALCLs but absent in 97 percent of conventional types of LyP. Histologically, lesions showed a biphasic growth pattern, with small cerebriform lymphocytes in the epidermis and larger transformed lymphocytes in the dermis. All had a T cell immunophenotype but were often negative for both CD4 and CD8. The pathologic features raised the possibility of an aggressive T cell lymphoma such as transformed mycosis fungoides. However, no patient developed disseminated skin disease or extracutaneous spread. Untreated lesions regressed spontaneously, characteristic of LyP [<a href="#rid8">8</a>].</p><p>A novel, recurrent <em>NPM1-TYK2</em> gene fusion has been reported in biopsy samples of LyP and PC-ALCL [<a href="#rid38">38</a>]. This finding supports the hypothesis that <em>NPM1-TYK2</em> mediates the activation of STAT1/3/5 signaling to promote cell proliferation. The inactivation of <em>TYK2</em> significantly diminished proliferation, suggesting that <em>TYK2</em> is an oncogenic driver kinase and a potential therapeutic target in a subset of CD30<sup>+</sup> cutaneous LPDs.</p><p class="headingAnchor" id="H17871994"><span class="h2">Spontaneous regression</span><span class="headingEndMark"> — </span>The mechanisms underlying the spontaneous regression of LyP lesions are unknown. The prevailing hypothesis is that the coexpression of CD30 and the death receptor CD95 (Fas) ligand in LyP lesions may be responsible for the self-regression of LyP lesions by enhanced apoptosis of proliferating cells [<a href="#rid39">39</a>]. This hypothesis is supported by several observations:</p><p class="bulletIndent1"><span class="glyph">●</span>LyP and plaque-stage mycosis fungoides (MF) have a higher apoptosis/proliferation ratio than more aggressive cutaneous lymphomas such as tumor stage MF, cutaneous T cell lymphomas with tumor masses, or cutaneous B cell lymphoma [<a href="#rid40">40,41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The large atypical CD30<sup>+</sup> cells of LyP have a low expression of the anti-apoptotic Bcl-2 protein [<a href="#rid42">42,43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pro-apoptotic protein BAX is expressed at higher levels in LyP and CD30<sup>+</sup> ALCL than in systemic CD30<sup>+</sup> lymphoma, which does not undergo spontaneous regression and has an aggressive clinical behavior [<a href="#rid41">41</a>].</p><p></p><p class="headingAnchor" id="H18325874"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H8448414"><span class="h2">Histologic features</span><span class="headingEndMark"> — </span>The histology of lymphomatoid papulosis (LyP) varies according to the age of the lesion. Early lesions show a limited perivascular collection of lymphocytes with few inflammatory cells and large atypical cells. As lesions evolve, there is accumulation of dermal lymphocytes admixed with large atypical cells resembling immunoblasts, including bi- and multi-nucleated forms similar to Hodgkin/Reed-Sternberg cells of Hodgkin lymphoma  (<a class="graphic graphic_picture graphicRef82763" href="/z/d/graphic/82763.html" rel="external">picture 1A</a>). </p><p>A variable number of inflammatory cells, mostly neutrophils and eosinophils, are also seen. Neutrophils are usually found within the lumina of small dermal capillaries and serve as a useful diagnostic marker of LyP. Some degree of neutrophilic infiltration of the overlying epidermis is commonly seen, especially in advanced lesions, and may be associated with initial ulceration. Fully developed LyP lesions typically have a wedge-shaped configuration with a deep-lying apex  (<a class="graphic graphic_picture graphicRef82764" href="/z/d/graphic/82764.html" rel="external">picture 1B</a>). </p><p>There are six major histologic types of LyP lesions:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type A</strong> – Type A is the most common (approximately 75 percent of cases) and is characterized by a wedge-shaped infiltrate of scattered or clustered large atypical CD30<sup>+</sup> cells, intermingled with numerous inflammatory cells, such as small lymphocytes, neutrophils, eosinophils, and histiocytes  (<a class="graphic graphic_picture graphicRef82764" href="/z/d/graphic/82764.html" rel="external">picture 1B</a>). Type A resembles the polymorphous infiltrates of Hodgkin lymphoma. Mitoses are frequent and may be atypical. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type B </strong>–<strong> </strong>Type B lesions show a predominant epidermotropic infiltrate of smaller atypical CD30<sup>+</sup> or CD30<sup>-</sup> cells with cerebriform nuclei that histologically resembles mycosis fungoides (MF). Unlike MF, LyP type B infiltrates are associated with papular lesions that regress spontaneously.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type C </strong>–<strong> </strong>Type C lesions contain large dermal clusters or sheets of large atypical CD30<sup>+</sup> cells with relatively few inflammatory cells. These lesions resemble foci of cutaneous anaplastic large cell lymphoma (ALCL), and the distinction from ALCL is largely based on clinical presentation. (See  <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type D </strong>–<strong> </strong>Type D (CD8<sup>+</sup> cytotoxic T cell lymphoma-like) lesions are characterized by a pagetoid infiltrate of epidermotropic small to medium-sized atypical CD8<sup>+</sup> and CD30<sup>+</sup> lymphoid cells that resembles primary cutaneous aggressive epidermotropic CD8<sup>+</sup> cytotoxic T cell lymphoma [<a href="#rid44">44,45</a>]. However, clinically, the lesions appear and behave as LyP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type E</strong> – Type E has consistent dermal angiocentric infiltrates of small and medium-sized to large pleomorphic cells expressing uniformly CD30 and focally CD8 that infiltrate the walls of small to medium-sized dermal, and in some cases subcutaneous, blood vessels  (<a class="graphic graphic_picture graphicRef90292" href="/z/d/graphic/90292.html" rel="external">picture 2</a>). Vasculitis with fibrin deposition in vessel walls is described. Vascular thrombosis occurs in one-half of cases. Extensive extravasation of erythrocytes from damaged blood vessels also may occur [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LyP with DUSP22:6p25.3 rearrangement</strong> – This variant has a distinctive biphasic histology with small to medium-sized epidermotropic cerebriform lymphocytes and large pleomorphic dermal lymphocytes. CD30 staining is biphasic with usual stronger staining of dermal compared with epidermal cells. Atypical cells are often double-negative for CD4 and CD8 or CD8<sup>+</sup>. Most patients with LyP and 6p25.3 gene rearrangement are older adults [<a href="#rid8">8</a>].</p><p></p><p>Follicular LyP is another rare histopathologic variant characterized by a perifollicular infiltrate of CD30<sup>+</sup> atypical medium to large lymphoid cells, with variable degree of folliculotropism, follicular mucinosis, and presence of neutrophils in the hair follicle infundibula [<a href="#rid47">47</a>]. Rare, granulomatous and syringotropic variants have been described [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H18325881"><span class="h2">Immunophenotype</span><span class="headingEndMark"> — </span>The large atypical immunoblast-like cells of LyP have the phenotype of activated T cells expressing Hodgkin lymphoma-related antigens [<a href="#rid49">49</a>]. In type A and type C LyP, these cells have an aberrant T cell phenotype lacking one or more common T cell antigens (CD3, CD2, CD5, or CD7) and are usually CD4<sup>+</sup> and less often CD8<sup>+</sup>. They express CD30, CD25, HLA-DR and CD71, and occasionally CD15 or CD56. In type B LyP, the atypical cells with cerebriform nuclei have a CD3<sup>+</sup>, CD4<sup>+</sup>, CD8<sup>-</sup> phenotype and variable expression of CD30. Large cells in types D are CD30<sup>+</sup> CD8<sup>+</sup> and in type E are CD30<sup>+</sup> and CD8<sup>+</sup> in most cases. In LyP with 6p25.3 rearrangement, large cells are often double-negative for CD4 and CD8, but CD3- and TCR-beta F1-positive. CD30 is positive in both dermal and smaller epidermotropic cells [<a href="#rid8">8</a>].</p><p>Cytotoxic granules (granzyme B, perforin, T cell intracellular antigen [TIA]-1) can be found within the cytoplasm in approximately 50 percent of cases [<a href="#rid50">50</a>].</p><p>SATB1 (special AT-rich sequence-binding protein 1), a thymocyte nuclear chromatin organizer that plays a crucial role in T cell development, was found to be overexpressed in the CD30<sup>+</sup> anaplastic T cells in CD30<sup>+</sup> cutaneous lymphoproliferative disorders (LPDs), including LyP [<a href="#rid51">51</a>]. In a series of 54 patients with CD30<sup>+</sup> cutaneous LPD (12 with LyP), SATB1<sup>+</sup> cases demonstrated a T helper (Th)-17 cytokine profile in anaplastic T cells and a marked inflammatory histopathologic response, including more prominent epidermal hyperplasia, epidermotropism, neutrophilic infiltrate, and vasculitic changes [<a href="#rid52">52</a>]. Interestingly, SATB1<sup>+</sup> cases responded better to combined therapy of low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and interferon-alfa-2b. </p><p class="headingAnchor" id="H610323182"><span class="h2">Genetic features</span><span class="headingEndMark"> — </span>Clonal rearrangement of the <em>TCR</em> genes is observed in 40 to 100 percent of cases of LyP [<a href="#rid19">19-22</a>]. Identical rearrangements have been demonstrated in LyP lesions and associated lymphomas [<a href="#rid24">24-32</a>]. The t(2;5)(p23;q35) translocation involving the anaplastic lymphoma kinase (ALK), a marker of systemic ALCL, is not found in LyP or in cutaneous ALCL. Only one recurrent rearrangement of 6p25.3 has been described in a small group of older adult patients [<a href="#rid8">8</a>]. </p><p class="headingAnchor" id="H7533382"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Lymphomatoid papulosis (LyP) manifests as a chronic, recurrent eruption of papules and nodules that spontaneously regress. Some patients, particularly children, experience pruritus associated with the eruption [<a href="#rid23">23,53</a>]. Other systemic symptoms, including fever, sweats, or weight loss, are absent in patients with uncomplicated LyP. Their presence raises the suspicion of an associated systemic lymphoma and warrants further evaluation. (See <a class="local">'Further diagnostic evaluation'</a> below.)</p><p>The lesions of LyP are grouped or generalized and usually coexist in different developmental stages  (<a class="graphic graphic_picture graphicRef77791" href="/z/d/graphic/77791.html" rel="external">picture 3C</a>). Early lesions appear as small erythematous or violaceous papules, which evolve to larger papules or nodules that may develop central hemorrhage, necrosis, and crusting and subsequently disappear in three to eight weeks  (<a class="graphic graphic_picture graphicRef82762 graphicRef71441 graphicRef77791" href="/z/d/graphic/82762.html" rel="external">picture 3A-C</a>).</p><p>The lesions of LyP are generally smaller than 2 cm. Larger lesions are occasionally seen and are clinically indistinguishable from those of primary or secondary anaplastic large cell lymphoma (ALCL  (<a class="graphic graphic_picture graphicRef83092 graphicRef83091 graphicRef83089" href="/z/d/graphic/83092.html" rel="external">picture 4A-C</a>)) [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)", section on 'Primary cutaneous ALCL'</a>.)</p><p>A type E variant with clinical and histologic manifestations simulating highly aggressive angiocentric and angiodestructive T cell lymphoma has been described [<a href="#rid46">46,55</a>]. Patients present with a few papulonodular lesions that rapidly evolve to large ulcerations covered by a hemorrhagic and necrotic crust  (<a class="graphic graphic_picture graphicRef90290" href="/z/d/graphic/90290.html" rel="external">picture 5</a>). (See <a class="local">'Histologic features'</a> above.)</p><p>There is no preferential site of involvement. Lesions typically occur on the extremities and may involve the hands, face, and genitalia. Mucous membranes (eg, oral or vaginal mucosa), are rarely involved [<a href="#rid56">56-58</a>]. Localized or regional forms have been reported in a few patients [<a href="#rid59">59-62</a>]. Localized, circumscribed lesions can resemble limited plaque mycosis fungoides and have been reported to progress similarly to untreated mycosis fungoides [<a href="#rid59">59</a>]. Follicular and pustular variants have also been described [<a href="#rid63">63-66</a>].</p><p>The evolution of an individual lesion generally occurs over three to eight weeks; larger nodules may take months to heal. As lesions resolve, they may take on a brownish-red color and disappear, leaving an area of increased pigmentation or scarring  (<a class="graphic graphic_picture graphicRef71441" href="/z/d/graphic/71441.html" rel="external">picture 3B</a>). Ulcerated and necrotic lesions may leave hypo- or hyperpigmented, depressed, varioliform scars.</p><p>The duration of the disease is highly variable. Crops of lesions may recur and regress for months, years, or even decades.</p><p class="headingAnchor" id="H1262335478"><span class="h1">ASSOCIATED HEMATOLOGIC MALIGNANCIES</span><span class="headingEndMark"> — </span>Patients with lymphomatoid papulosis (LyP) have a lifelong increased risk of hematologic malignancies, most frequently mycosis fungoides (MF) and cutaneous or systemic anaplastic large cell lymphoma (ALCL) and, less commonly, B cell or Hodgkin lymphoma [<a href="#rid4">4,6,67,68</a>]. LyP-associated hematologic malignancies may occur before, concurrent with, or after the onset of LyP [<a href="#rid4">4,6,23,28,53,67,69</a>]. In the largest cohort study that included 504 patients with LyP, 78 patients (15.5 percent) developed a hematologic malignancy after a median follow-up of 120 months [<a href="#rid68">68</a>]. Of these 78 patients, 31 had MF, 29 had ALCL, and 19 had other hematologic malignancies, mainly of B cell or myeloid origin. Some cases originally believed to be Hodgkin lymphoma may actually represent T cell lymphomas with Reed-Sternberg-like cells expressing CD30 and CD15 [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)"</a> and  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a> and  <a class="medical medical_review" href="/z/d/html/4691.html" rel="external">"Hodgkin lymphoma: Epidemiology and risk factors"</a>.)</p><p>A clonal relationship between LyP and the associated lymphomas has been established in most of the cases analyzed [<a href="#rid24">24-32</a>]. The finding of identical <em>TCR</em> gene rearrangements in LyP and LyP-associated lymphomas [<a href="#rid25">25</a>] suggests that both disorders arise from a common lymphoid progenitor [<a href="#rid71">71</a>]. However, the molecular mechanisms underlying the progression of LyP to malignant lymphoma are unknown. The progression of LyP to ALCL appears to be mediated by the loss of cell growth regulation induced by inactivating mutations of cell surface receptors for transforming growth factor (TGF)-beta [<a href="#rid33">33,34,72</a>].</p><p>In a study of 106 French patients with LyP, the mean age of patients who developed lymphoma was 12 years older than patients without lymphoma [<a href="#rid73">73</a>]. There are no other clinical or histopathologic criteria to predict the progression of LyP to a malignant lymphoma [<a href="#rid4">4</a>]. Observational studies have identified several potential markers of increased risk, including monoclonal <em>TCR</em> gene rearrangement [<a href="#rid73">73,74</a>]; coexistence of different histologic types of LyP in an individual patient; B and C histologic subtypes [<a href="#rid69">69</a>]; fascin expression [<a href="#rid75">75</a>]; or high blood levels of soluble CD30, CD25, interleukin (IL) 6, and IL-8. [<a href="#rid76">76</a>]. However, their role in disease progression has not been established. </p><p class="headingAnchor" id="H7711520"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H2403092050"><span class="h2">Clinical suspicion</span><span class="headingEndMark"> — </span>The diagnosis of lymphomatoid papulosis (LyP) is clinically suspected in a patient presenting with:</p><p class="bulletIndent1"><span class="glyph">●</span>History of a <strong>recurrent</strong> eruption of papules and nodules that evolve and regress spontaneously in the absence of systemic B symptoms. (See  <a class="medical medical_review" href="/z/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults", section on 'B symptoms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Grouped or generalized papules and nodules in different stages of evolution, some with central ulceration, crusting, or eschar  (<a class="graphic graphic_picture graphicRef74972 graphicRef54022 graphicRef82762 graphicRef71441 graphicRef77791" href="/z/d/graphic/74972.html" rel="external">picture 3A-E</a>) (see <a class="local">'Clinical features'</a> above)</p><p></p><p class="headingAnchor" id="H401108846"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>A skin biopsy for histopathologic, immunohistochemical, and molecular genetic evaluation is necessary to confirm the diagnosis. The complete excision of two or more inflammatory lesions without signs of necrosis or involution provides the optimal specimens for the pathologist.</p><p>The definitive diagnosis is based upon the correlation of the clinical appearance and course of the skin lesions with the following histologic, immunophenotypic, and cytogenetic features [<a href="#rid77">77</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A wedge-shaped infiltrate of large atypical T cells, intermingled with numerous inflammatory cells, including small lymphocytes, neutrophils, eosinophils, and histiocytes (type A LyP)  (<a class="graphic graphic_picture graphicRef82763 graphicRef82764" href="/z/d/graphic/82763.html" rel="external">picture 1A-B</a>) (see <a class="local">'Histologic features'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Expression of CD30 on immunohistochemistry  (<a class="graphic graphic_picture graphicRef82764" href="/z/d/graphic/82764.html" rel="external">picture 1B</a>) (see <a class="local">'Immunophenotype'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clonal rearrangement of the <em>TCR</em> genes (in 40 to 100 percent of cases) (see <a class="local">'Genetic features'</a> above)</p><p></p><p class="headingAnchor" id="H20514972"><span class="h2">Diagnostic pitfalls</span><span class="headingEndMark"> — </span>The diagnosis of LyP may be difficult or delayed in some patients for several reasons:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histologic variability</strong> – The histology of LyP is highly variable. The histologic subtypes of LyP probably represent evolutionary stages of the skin lesions and may be seen in individual patients at presentation or at different times in the course of the disease. (See <a class="local">'Histologic features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histologic overlap</strong> – There is considerable clinical, histologic, and immunophenotypic overlap between LyP and primary cutaneous anaplastic large cell lymphoma (PC-ALCL). As an example, the finding of scattered CD30<sup>+</sup> blast cells in a background of mixed inflammatory infiltrate is highly suggestive of LyP, but may be also seen in PC-ALCL presenting with ulcerated lesions [<a href="#rid2">2</a>]. Conversely, dermal clusters or sheets of large atypical CD30<sup>+</sup> cells with relatively few inflammatory cells are characteristic of PC-ALCL, but can also be found in patients with clinical presentation and course of LyP. (See <a class="local">'CD30+ lymphoproliferative diseases'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mimics of CD30</strong><strong><sup>+</sup></strong><strong> lymphoproliferative diseases</strong> – CD30<sup>+</sup> lymphoid cells can be seen in a wide range of inflammatory and infectious disorders and other lymphoid neoplasms that may be clinically and histologically indistinguishable from LyP. Appropriate clinicopathologic correlation is <strong>essential</strong> for accurate diagnosis. (See <a class="local">'CD30+ inflammatory and infectious diseases'</a> below.)</p><p></p><p class="headingAnchor" id="H2469467409"><span class="h1">FURTHER DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>Following the diagnosis of lymphomatoid papulosis (LyP), additional evaluation may be needed in some patients to exclude a concurrent malignant lymphoma. Elements of history that increase the risk of malignant lymphoma include:</p><p class="bulletIndent1"><span class="glyph">●</span>Previous lymphoid neoplasm, particularly Hodgkin lymphoma, systemic anaplastic large cell lymphoma (ALCL), or mycosis fungoides (MF)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic symptoms, such as unexplained weight loss, fever, night sweats, shortness of breath, abdominal fullness</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV infection or immunosuppressive therapy</p><p></p><p>Examination findings that may suggest malignant lymphoma include:</p><p class="bulletIndent1"><span class="glyph">●</span>Morphology, size, and extent of skin lesions (isolated or few lesions that are larger than 2 cm are more suggestive of cutaneous ALCL than LyP  (<a class="graphic graphic_picture graphicRef83092 graphicRef83091 graphicRef83089 graphicRef83095" href="/z/d/graphic/83092.html" rel="external">picture 4A-D</a>))</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythematous, scaly patches and plaques (suggestive of mycosis fungoides  (<a class="graphic graphic_picture graphicRef80073 graphicRef60650 graphicRef52131 graphicRef73078" href="/z/d/graphic/80073.html" rel="external">picture 6A-D</a>))</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lymph node enlargement</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatic or splenic enlargement</p><p></p><p>Additional laboratory investigations that may be helpful to exclude a malignant lymphoma include:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood cell count and differential</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Examination of a peripheral blood smear for the presence of atypical cells (absent in LyP)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Routine biochemistry tests, including lactate dehydrogenase (LDH)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Human T-lymphotropic virus I (HTLV-I) serology in endemic areas to exclude adult T cell leukemia-lymphoma (see  <a class="medical medical_review" href="/z/d/html/8316.html" rel="external">"Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology", section on 'Epidemiology and transmission'</a>)</p><p></p><p>Imaging studies, including chest radiograph, ultrasonography of abdomen and pelvis, or computed tomography scan, are considered optional examinations in patients with typical LyP, normal laboratory tests, and absence of palpable enlarged lymph nodes, hepatosplenomegaly, and systemic symptoms [<a href="#rid77">77</a>].</p><p>However, a chest radiograph at presentation may be helpful to exclude a mediastinal mass from occult Hodgkin or non-Hodgkin lymphoma. A chest radiograph also may be warranted for patients who will be treated with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> because pre-existing lung disease may be a risk factor for lung toxicity. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a> and  <a class="medical medical_review" href="/z/d/html/4372.html" rel="external">"Methotrexate-induced lung injury"</a>.)</p><p>A liver biopsy should be considered in patients with abnormal liver function tests and/or history of excess alcohol use, hepatitis, or diabetes mellitus. </p><p class="headingAnchor" id="H18325888"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of lymphomatoid papulosis (LyP) includes other lymphoproliferative diseases expressing CD30 and several inflammatory and reactive disorders that contain CD30<sup>+</sup> cells and mimic LyP clinically and histologically [<a href="#rid54">54</a>]. The clinicopathologic characteristics of the main disorders that should be differentiated from LyP are summarized in the table  (<a class="graphic graphic_table graphicRef75494" href="/z/d/graphic/75494.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H8448437"><span class="h2">CD30+ lymphoproliferative diseases</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary cutaneous anaplastic large cell lymphoma</strong> – Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) usually manifests as a solitary, firm, large, and sometimes ulcerated nodule  (<a class="graphic graphic_picture graphicRef83089" href="/z/d/graphic/83089.html" rel="external">picture 4C</a>). Approximately 20 percent of patients have multifocal disease  (<a class="graphic graphic_picture graphicRef83092 graphicRef83091" href="/z/d/graphic/83092.html" rel="external">picture 4A-B</a>). CD30 is expressed by at least 75 percent of the large atypical T cells, and clonal <em>TCR</em> gene rearrangement is found in 90 percent of cases. Unlike systemic ALCL, primary cutaneous ALCL usually lacks expression of epithelial membrane antigen (EMA) and anaplastic lymphoma kinase (ALK). However, an ALK protein variant localized to the cytoplasm and distinct from the nuclear/cytoplasmic variant resulting from the nucleophosmin (NPM):ALK translocation has been detected in a few cases of primary cutaneous ALCL, some of which also expressed EMA [<a href="#rid78">78-82</a>]. </p><p></p><p class="bulletIndent1">When NPM-ALK is detected as a nuclear/cytoplasmic stain, a thorough investigation should be done to exclude nodal systemic ALCL [<a href="#rid82">82,83</a>]. ALK protein is essentially absent in LyP [<a href="#rid84">84</a>]. If an <em>ALK</em> gene rearrangement is detected, secondary skin lesions of systemic ALCL should be suspected. Cutaneous presentations of ALK-positive systemic ALCL associated with regional lymphadenopathy have been reported in children following insect bites [<a href="#rid85">85,86</a>]. (See  <a class="medical medical_review" href="/z/d/html/99486.html" rel="external">"Primary cutaneous anaplastic large cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary skin lesions of systemic anaplastic large cell lymphoma</strong> – Most systemic anaplastic large cell lymphomas (ALCLs) carry the t(2;5)(p23;q35) translocation and express ALK, which is absent in LyP. (See  <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)", section on 'Primary cutaneous ALCL'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transformed mycosis fungoides and Sézary syndrome</strong> – Approximately one-half of transformed mycosis fungoides (MF) and Sézary syndrome (SS) are CD30<sup>+</sup>. A previous history of patch or plaque MF or erythroderma clarifies the diagnosis, although LyP lesions may be coexistent with MF [<a href="#rid25">25,87</a>]. LyP type B is difficult to distinguish histologically from papular MF, in which lesions persist and may eventually become associated with typical patches and plaques [<a href="#rid88">88,89</a>]. (See  <a class="medical medical_review" href="/z/d/html/83281.html" rel="external">"Staging and prognosis of mycosis fungoides and Sézary syndrome", section on 'Transformation to large-cell histology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adult T cell leukemia-lymphoma</strong> – Adult T cell leukemia-lymphoma (ATLL) is a peripheral T cell leukemia-lymphoma caused by the human retrovirus HTLV-1. Most cases have an acute onset with generalized lymphadenopathy. All patients with ATLL have serologic antibodies to HTLV-1. Cutaneous involvement occurs in approximately 50 percent of cases. Large blast-like cells can be CD30<sup>+</sup> but are ALK<sup>-</sup>. (See  <a class="medical medical_review" href="/z/d/html/4697.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hodgkin lymphoma </strong>– Skin involvement is rare in Hodgkin lymphoma, and primary cutaneous forms are even rarer  (<a class="graphic graphic_picture graphicRef83095" href="/z/d/graphic/83095.html" rel="external">picture 4D</a>). The Reed-Sternberg cells of Hodgkin lymphoma are CD30<sup>+</sup> and CD15<sup>+</sup>. The latter is less frequently expressed in LyP. (See  <a class="medical medical_review" href="/z/d/html/4691.html" rel="external">"Hodgkin lymphoma: Epidemiology and risk factors"</a>.)</p><p></p><p>Other lymphoid neoplasms that can have CD30-expressing neoplastic T cells may be confused with LyP in the absence of proper clinical context:</p><p class="bulletIndent1"><span class="glyph">●</span>Gamma/delta T cell lymphomas commonly present as ulcerating tumors in the extremities (usually legs) of adults. Lesions are larger than in LyP and ulcers often expose subcutaneous fat not seen in LyP [<a href="#rid90">90</a>]. (See  <a class="medical medical_review" href="/z/d/html/4744.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T cell lymphoma", section on 'Primary cutaneous gamma/delta T cell lymphoma'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subcutaneous panniculitis-like T cell lymphoma (SPTCL) presents as palpable cutaneous nodules in children and adults but rarely ulcerates as in LyP [<a href="#rid91">91</a>]. Ringing of fat cells by tumor cells characteristic of SPTCL is infrequently seen in CD30<sup>+</sup> cutaneous ALCL but rarely in LyP in which the CD30<sup>+</sup> cells are usually confined to the dermis. (See  <a class="medical medical_review" href="/z/d/html/4744.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of subcutaneous panniculitis-like T cell lymphoma"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hydroa vacciniforme-like lymphoma is an Epstein-Barr virus (EBV)-driven lymphoproliferative disease affecting children and adolescents from Asia, Central and South America, and Mexico [<a href="#rid92">92,93</a>]. Clinical features include facial edema and vesicles, small necrotic areas, crusts, and pitted scars involving the face and sun-exposed areas  (<a class="graphic graphic_picture graphicRef104943" href="/z/d/graphic/104943.html" rel="external">picture 7</a>). EBV is detected in CD30<sup>+</sup> cells but is absent in LyP. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type E LyP can mimic angiocentric lesions of gamma-delta T cell lymphoma and NK/T cell lymphoma [<a href="#rid94">94</a>]. (See  <a class="medical medical_review" href="/z/d/html/4712.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral T cell lymphoma, not otherwise specified (PTCL, NOS) infrequently presents as a primary skin tumor in absence of lymphadenopathy [<a href="#rid95">95,96</a>]. Lesions contain sheets of tumor cells of varied size without inflammatory cells, whereas inflammatory cells are characteristic of LyP. Whereas LyP and PC-ALCL typically show disturbed expression of the T cell receptor/CD3 complex (CD3-gamma, -delta, -epsilon, -zeta) and associated signaling molecules (Lck, ZAP-70, LAT, bcl-10, Carma1, NFATc1, c-Jun, c-Fos, Syk), the full expression program required for T cell receptor signaling is retained in PTCL, NOS, facilitating their differential diagnosis [<a href="#rid97">97</a>]. (See  <a class="medical medical_review" href="/z/d/html/4694.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified"</a>.) </p><p></p><p class="headingAnchor" id="H8448445"><span class="h2">CD30+ inflammatory and infectious diseases</span><span class="headingEndMark"> — </span>Several inflammatory and reactive disorders may contain a significant number of CD30<sup>+</sup> cells and mimic LyP clinically or histologically [<a href="#rid54">54,98</a>]. However, the reactive or inflammatory disorders are less likely to have dominant T cell clones, especially identical clones in multiple biopsies. These disorders, sometimes referred to as CD30<sup>+</sup> pseudolymphomas, include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pityriasis lichenoides </strong>– Pityriasis lichenoides et varioliformis acuta (PLEVA) is a skin disease of unknown etiology clinically characterized by the eruption of crops of papules that evolve to necrotic lesions and eventually resolve leaving varioliform scars  (<a class="graphic graphic_picture graphicRef57911 graphicRef83096" href="/z/d/graphic/57911.html" rel="external">picture 8A-B</a>). LyP and PLEVA may have overlapping clinical, histopathologic, and molecular features [<a href="#rid99">99</a>]. With few exceptions [<a href="#rid99">99</a>], the lymphocytic infiltrate in PLEVA is predominantly CD8<sup>+</sup> with few large atypical CD30<sup>+</sup> cells. A dominant T cell clone was detected in 13 of 20 cases (65 percent) in one study [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent1">Pityriasis lichenoides chronica (PLC) may be more difficult to distinguish from LyP because the predominant lymphoid infiltrate can be CD4<sup>+</sup>. In children, the two entities may coexist [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/15282.html" rel="external">"Pityriasis lichenoides et varioliformis acuta (PLEVA)"</a> and  <a class="medical medical_review" href="/z/d/html/15287.html" rel="external">"Pityriasis lichenoides chronica"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reactions to arthropod bites/nodular scabies</strong> – Chronic reactions to insect bites and nodular scabies may simulate LyP clinically and histologically  (<a class="graphic graphic_picture graphicRef60849 graphicRef75169 graphicRef83093" href="/z/d/graphic/60849.html" rel="external">picture 9A-C</a>). The dermis contains a dense inflammatory infiltrate of lymphoid cells and histiocytes, with an admixture of eosinophils and plasma cells and atypical mononuclear cells with hyperchromatic nuclei. A history of exposure and the presence of symptoms (eg, intense pruritus) may help in differentiating arthropod bites from LyP. (See  <a class="medical medical_review" href="/z/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis", section on 'Classic scabies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lymphomatoid drug eruption</strong> – A lymphomatoid eruption is a rare type of drug reaction clinically characterized by indurated papules or plaques  (<a class="graphic graphic_picture graphicRef83094" href="/z/d/graphic/83094.html" rel="external">picture 10</a>). Cases associated with the presence of large atypical CD30<sup>+</sup> T cells on histologic examination have been reported following the administration of antibiotics, antiepileptics, or biologics [<a href="#rid98">98,101-104</a>]. The temporal relationship between the drug administration and skin eruptions and the disappearance of the rash after the drug suspension clarifies the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/15723.html" rel="external">"Cutaneous T cell pseudolymphomas", section on 'Lymphomatoid drug reaction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral infection </strong>– Cutaneous viral infections (orf and milker's nodule viruses, herpes simplex, varicella-zoster, molluscum contagiosum) may show large atypical CD30<sup>+</sup> cells on histologic examination [<a href="#rid98">98,105</a>]. In contrast to LyP, skin lesions caused by viruses do not have a waxing and waning clinical course and do not show T-cell-receptor (<em>TCR)</em> gene rearrangement on molecular genetic studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – CD30<sup>+</sup> T cells may also be found in skin lesions of atopic dermatitis [<a href="#rid106">106-109</a>], mycobacterial infection [<a href="#rid110">110</a>], syphilis, and leishmaniasis [<a href="#rid98">98</a>]. The history and clinical course are usually sufficient to differentiate these conditions from LyP.</p><p></p><p class="headingAnchor" id="H6481803"><span class="h1">INDICATIONS FOR REFERRAL</span><span class="headingEndMark"> — </span>If physical examination, blood tests, or imaging studies suggest extracutaneous lymphoproliferative disease associated with LyP, the patient should be referred to a hematologist/oncologist for appropriate diagnostic evaluation, staging, and treatment of possible malignancy. </p><p class="headingAnchor" id="H1353598"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H19844342"><span class="h2">General considerations</span><span class="headingEndMark"> — </span>Lymphomatoid papulosis (LyP) has a chronic course of years to decades of recurrent papulonodular lesions that undergo spontaneous regression after weeks or months. Treatment may hasten lesion healing and reduce the severity or prevent the eruption of new crops of lesions. However, none of the available treatment modalities alters the natural history of LyP or reduces the risk of developing an associated lymphoma. Thus, the short-term benefits of treatment should be weighed against potentially harmful side effects in the individual patient [<a href="#rid77">77,111</a>].</p><p class="headingAnchor" id="H339960644"><span class="h2">Patients with limited or asymptomatic disease</span><span class="headingEndMark"> — </span>For patients who have few asymptomatic lesions without scarring or other cosmetic concerns (eg, lesions not on the face or hands), a wait-and-see strategy is appropriate, depending upon patient preference [<a href="#rid77">77</a>]. If the patient desires treatment in an attempt to minimize the lesions or facilitate regression, super-high potency topical corticosteroids (group 1  (<a class="graphic graphic_table graphicRef62402" href="/z/d/graphic/62402.html" rel="external">table 2</a>)) are an option.</p><p>Skin lesions &gt;2 cm that do not regress spontaneously in eight weeks should be biopsied and sent for pathology to exclude primary cutaneous anaplastic large cell lymphoma (PC-ALCL) [<a href="#rid111">111</a>]. (See  <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)"</a>.)</p><p class="headingAnchor" id="H339960651"><span class="h2">Patients with extensive or symptomatic disease</span><span class="headingEndMark"> — </span>Observation may be acceptable in patients who do not wish treatment. Some patients may use topical corticosteroids to alleviate symptoms alone or in conjunction with other treatment options listed below.</p><p class="headingAnchor" id="H19844538"><span class="h3">Methotrexate</span><span class="headingEndMark"> — </span>We suggest low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (5 to 35 mg per week by oral or subcutaneous administration) as the initial therapy for adult patients with symptomatic or extensive disease or disease involving cosmetically sensitive areas (eg, face or hands) [<a href="#rid77">77</a>]. Treatment is usually started at 5 to 10 mg per week and increased by 2.5 to 5 mg per week or as tolerated to a maximum of 25 to 35 mg per week if a clinical improvement is not observed in four to eight weeks. Patients receiving weekly methotrexate should also receive <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">folic acid</a> 1 mg per day orally. </p><p>A complete response is indicated by the clearance of all the active lesions without the development of new lesions. A partial response is defined as the regression of at least 50 percent of the active lesions and development of fewer new lesions [<a href="#rid77">77</a>]. Maintenance treatment is often required for long-term control of disease in a majority of patients. Maintenance therapy is usually initiated after complete response; the dose is gradually decreased by 2.5 or 5 mg per week to the lowest effective dose.</p><p>The duration of treatment and maintenance treatment is based upon clinical response, occurrence of side effects, and patient's preference. The time to relapse after discontinuation of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> is variable and should be assessed in the individual patient.</p><p class="headingAnchor" id="H57040901"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>The efficacy of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> for LyP has not been evaluated in randomized trials. Its use is based upon evidence of efficacy from small observational studies and expert consensus [<a href="#rid77">77,112</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study including 45 patients with LyP treated with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> 15 to 25 mg weekly, 20 patients (44 percent) did not develop new lesions and 19 patients (42 percent) developed only a few lesions during the treatment [<a href="#rid113">113</a>]. After discontinuation of therapy, 10 of 40 patients did not relapse during a follow-up period of 24 to 227 months. Patients with relapsing disease required maintenance treatment for months or years. Side effects were reported in 77 percent of patients, including hepatic fibrosis in 5 of 10 patients treated with methotrexate for more than three years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, 28 adult patients with extensive papulonecrotic and nodular skin lesions or cosmetically concerning lesions were treated with oral <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> 5 to 25 mg per week (median dose 10 mg per week) for 1 to 216 months (median 37 months) [<a href="#rid114">114</a>]. Excellent or good disease control was achieved in 24 patients in three to four weeks. Transient elevation of liver enzymes occurred in 10 patients during the first month of treatment; two patients discontinued treatment because of persistent elevated liver enzymes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, 25 patients with LyP were treated with oral <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> 20 to 30 mg per week for a minimum of six months, followed by a two- to six-month weaning period [<a href="#rid115">115</a>]. Twenty-two patients had a partial or complete response, but only 6 were successfully weaned off the drug and maintained the response for six months or longer, whereas 16 remained methotrexate dependent.</p><p></p><p class="headingAnchor" id="H1436730"><span class="h4">Contraindications and adverse effects</span><span class="headingEndMark"> — </span>Important contraindications to <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> therapy include liver disease, renal disease, and pregnancy or planned pregnancy (for both females and males) [<a href="#rid116">116,117</a>]. Before initiating long-term methotrexate therapy, screening for hepatitis B and hepatitis C virus infection is recommended. In patients with infection, this allows a decision whether to avoid the use of methotrexate, to try to eradicate the viral infection before initiating therapy, or to suppress viral replication during immunosuppressive therapy.</p><p>Minor adverse effects, including nausea, stomach upset, headache, and fatigue, occur in most patients treated with low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. Hepatotoxicity, pulmonary fibrosis, and myelosuppression are serious adverse effects of methotrexate treatment and may infrequently occur with low-dose therapy. (See  <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a>.)</p><p class="headingAnchor" id="H432319050"><span class="h4">Monitoring</span><span class="headingEndMark"> — </span>Serum aminotransferases and peripheral blood cell count should be obtained twice monthly in the first month, then every 4 to 12 weeks, to detect hepatic and hematologic toxicity during long-term treatment with <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>. Blood should be drawn on the day before the once-weekly methotrexate dose is administered for accurate assessment.</p><p>Guidelines for dose adjustment for patients with abnormal liver function tests are presented separately. (See  <a class="medical medical_review" href="/z/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease"</a>.)</p><p class="headingAnchor" id="H82845666"><span class="h3">Phototherapy</span><span class="headingEndMark"> — </span>We suggest psoralen and ultraviolet A (PUVA) therapy for patients with LyP whose disease does not respond to <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> or patients for whom methotrexate is contraindicated. PUVA is administered twice weekly for six to eight weeks or until clearance [<a href="#rid111">111</a>]. Maintenance therapy with one treatment session per week may be needed to prevent relapses. (See  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy", section on 'Treatment protocols'</a>.)</p><p>The efficacy of PUVA for the treatment of LyP has not been evaluated in clinical trials. Its use is supported by a few case series and evidence of efficacy in other types of cutaneous lymphoproliferative disorders (eg, mycosis fungoides) [<a href="#rid4">4,111</a>]. In a review of 19 patients treated with PUVA, a complete response was reported in 5 and a partial response in 13 [<a href="#rid77">77</a>]. Bath PUVA has been used for treatment of LyP in children [<a href="#rid118">118-120</a>].</p><p>Narrowband ultraviolet B (NBUVB) phototherapy or, if available, ultraviolet A1 (UVA1; long-wave [340 to 400 nm] ultraviolet A [UVA]) phototherapy, which do not require the oral or topical administration of psoralens, may be alternatives to PUVA. In one study, UVA1 phototherapy induced a complete response in five of seven patients [<a href="#rid121">121</a>]. Three patients relapsed between 1 and 20 months after discontinuation but responded to a second treatment cycle.</p><p class="headingAnchor" id="H82845833"><span class="h3">Other therapies</span><span class="headingEndMark"> — </span>Aggressive treatment of LyP with multiagent chemotherapy is inappropriate. In patients with associated lymphomas, treatment of lymphoma with multiagent chemotherapy does not alter the clinical course of LyP [<a href="#rid122">122,123</a>]. Therapies that seemed to be effective when used alone or in combination in small case series or in single patients include:</p><p class="bulletIndent1"><span class="glyph">●</span>Photodynamic therapy [<a href="#rid124">124</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Targeted phototherapy [<a href="#rid125">125</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Oral or topical retinoids (<a class="drug drug_general" data-topicid="8695" href="/z/d/drug information/8695.html" rel="external">bexarotene</a>) [<a href="#rid126">126</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="91010" href="/z/d/drug information/91010.html" rel="external">Topical mechlorethamine</a> and <a class="drug drug_general" data-topicid="9206" href="/z/d/drug information/9206.html" rel="external">carmustine</a> [<a href="#rid127">127</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Anti-CD30 monoclonal antibody-drug-conjugate (<a class="drug drug_general" data-topicid="16806" href="/z/d/drug information/16806.html" rel="external">brentuximab vedotin</a>) [<a href="#rid128">128,129</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> plus interferon-alfa-2b in LyP with Th-17 phenotype [<a href="#rid51">51</a>]</p><p></p><p class="headingAnchor" id="H7588131"><span class="h2">Treatment in children</span><span class="headingEndMark"> — </span>There is no consensus on treatment of LyP in children. In case series, no treatment or treatment with topical corticosteroids, oral antibiotics (macrolides or tetracyclines), ultraviolet B (UVB), or natural sunlight have been reported [<a href="#rid23">23,53,130-132</a>]. Low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and bath PUVA are additional therapeutic options [<a href="#rid118">118,119,133</a>].</p><p>For children with limited disease (few or small lesions), treatment is usually not necessary. When children require treatment because of cosmetic concerns or peer group pressure, we suggest topical corticosteroids or NBUVB phototherapy. Narrowband phototherapy is administered two to three times per week for six to eight weeks.</p><p>Low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (2.5 to 15 mg per week) may be an alternative for cases that do not respond to topical corticosteroids or NBUVB phototherapy.</p><p class="headingAnchor" id="H18325902"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Despite the increased risk of developing a cutaneous or nodal malignant lymphoma, the prognosis of lymphomatoid papulosis (LyP) is excellent in the vast majority of cases [<a href="#rid134">134</a>]. Patients with LyP who do not develop malignancy have a normal life expectancy. </p><p>The reported mortality rates from associated lymphomas are low [<a href="#rid4">4,69,74</a>]. In two case series, each with approximately 120 patients, associated lymphoid malignancy was detected in 19 and 14 percent before, after (up to 19 years), or concurrently with the development of LyP [<a href="#rid4">4,74</a>]. The mortality rate from associated lymphoma was approximately 2 percent in both series. In another study of 180 patients with LyP, 93 (52 percent) developed 114 hematologic malignancies and six (6 percent) died of their disease [<a href="#rid69">69</a>]. Patients with LyP may have an increased risk of nonlymphoid malignancies [<a href="#rid67">67</a>]. </p><p>LyP lesions may heal with scarring, especially in children. In small pediatric case series, varioliform scarring has been reported in approximately 80 percent of children [<a href="#rid23">23,131</a>].</p><p class="headingAnchor" id="H7855060"><span class="h1">FOLLOW-UP</span><span class="headingEndMark"> — </span>Patients with lymphomatoid papulosis (LyP) require long-term follow-up to monitor the disease course and response to treatment and lifelong surveillance for cutaneous or systemic lymphoma. Frequency of follow-up for those on treatment will depend on the specific treatment. For monitoring of disease course and surveillance, patients should be seen at 6- to 12-month intervals for:</p><p class="bulletIndent1"><span class="glyph">●</span>Reassessment of clinical history </p><p class="bulletIndent1"><span class="glyph">●</span>Complete skin examination</p><p class="bulletIndent1"><span class="glyph">●</span>Physical examination focused on lymph node, hepatic, or splenic enlargement</p><p></p><p class="headingAnchor" id="H3761617934"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122000.html" rel="external">"Society guideline links: Primary cutaneous lymphoma"</a>.)</p><p class="headingAnchor" id="H18325909"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and pathogenesis</strong> – Lymphomatoid papulosis (LyP) is a rare, chronic recurrent, self-healing papulonodular skin eruption with histologic features of a CD30<sup>+</sup> lymphoid proliferation of atypical T cells. The overexpression of CD30 on the large atypical T cell found in the skin lesions is the hallmark of LyP. Monoclonal rearrangement of the T cell receptor (<em>TCR</em>) genes has been detected in 40 to 100 percent of the LyP skin lesions. (See <a class="local">'Introduction'</a> above and <a class="local">'Etiology and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – LyP manifests as a recurrent eruption of papules and nodules with central necrosis and crusting that spontaneously resolve in three to eight weeks, leaving hyperpigmentation or scarring  (<a class="graphic graphic_picture graphicRef74972 graphicRef54022 graphicRef82762 graphicRef71441 graphicRef77791" href="/z/d/graphic/74972.html" rel="external">picture 3A-E</a>). (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated malignancies</strong> – Patients with LyP have an increased risk of associated lymphoid malignancy (mycosis fungoides, anaplastic large cell lymphoma, B cell or Hodgkin lymphoma) before, concurrent with, or after the onset of LyP. (See <a class="local">'Associated hematologic malignancies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of LyP is based upon the clinical appearance and course of the skin lesions and the evaluation of an excisional biopsy of a full-developed skin lesion. Histologic characteristics include a wedge-shaped inflammatory infiltrate containing large atypical CD30<sup>+</sup> cells  (<a class="graphic graphic_picture graphicRef82763 graphicRef82764" href="/z/d/graphic/82763.html" rel="external">picture 1A-B</a>). Clonal rearrangement of the <em>TCR</em> genes is found in 40 to 100 percent of cases. A careful clinicopathologic correlation is essential for a correct diagnosis. (See <a class="local">'Pathology'</a> above and <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional evaluation</strong> – At the time of diagnosis, patients with LyP should be further evaluated to exclude associated lymphoma. (See <a class="local">'Further diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of LyP includes lymphoproliferative and inflammatory or reactive disorders that contain CD30<sup>+</sup> cells and mimic LyP clinically and histologically  (<a class="graphic graphic_table graphicRef75494" href="/z/d/graphic/75494.html" rel="external">table 1</a>). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – None of the available treatment modalities alters the natural history of LyP or reduces the risk of developing an associated lymphoma. However, treatment may hasten lesion healing and reduce the severity or prevent the eruption of new crops of lesions (see <a class="local">'General considerations'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Limited disease</strong> – We suggest a wait-and-see strategy (observation) for patients who have limited or asymptomatic disease without scarring or other cosmetic concerns (eg, lesions not on the face or hands) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Patients with limited or asymptomatic disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Extensive disease</strong> – For patients with extensive or symptomatic disease, scarring, or cosmetic concerns, we suggest low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> as the initial therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The treatment is usually started at 5 to 10 mg per week orally or subcutaneously and increased by 2.5 mg per week or as tolerated to a maximum of 25 mg per week if clinical improvement is not observed. </p><p></p><p class="bulletIndent2">For patients for whom <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> is contraindicated and for patients with LyP that does not respond to methotrexate, we suggest psoralen and ultraviolet A (PUVA) therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). PUVA is administered twice weekly for six to eight weeks or until clearance. (See <a class="local">'Patients with extensive or symptomatic disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>In children</strong> – For children with symptomatic lesions, scarring, or cosmetic concerns, we suggest topical corticosteroids or narrowband ultraviolet B (NBUVB) therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Low-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> (2.5 to 15 mg per week) may be an alternative for children who do not respond to topical steroids or ultraviolet B (UVB). (See <a class="local">'Treatment in children'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The prognosis of LyP is excellent. However, because of the increased lifelong risk of developing a malignant lymphoma or other malignancy, patients with LyP require long-term follow-up. (See <a class="local">'Prognosis'</a> above and <a class="local">'Follow-up'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Macaulay WL. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign--histologically malignant. Arch Dermatol 1968; 97:23.</a></li><li><a class="nounderline abstract_t">Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768.</a></li><li><a class="nounderline abstract_t">Willemze R, Meijer CJ. Primary cutaneous CD30-positive lymphoproliferative disorders. Hematol Oncol Clin North Am 2003; 17:1319.</a></li><li><a class="nounderline abstract_t">Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95:3653.</a></li><li><a class="nounderline abstract_t">Assaf C, Gellrich S, Steinhoff M, et al. Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG). J Dtsch Dermatol Ges 2007; 5:662.</a></li><li><a class="nounderline abstract_t">Kunishige JH, McDonald H, Alvarez G, et al. Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. Clin Exp Dermatol 2009; 34:576.</a></li><li class="breakAll">Gomez ML. First World Congress on Cutaneous Lymphomas, Chicago, IL Sept 23-26, 2010. </li><li><a class="nounderline abstract_t">Karai LJ, Kadin ME, Hsi ED, et al. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol 2013; 37:1173.</a></li><li><a class="nounderline abstract_t">Kadin ME, Vonderheid EC, Weiss LM. Absence of Epstein-Barr viral RNA in lymphomatoid papulosis. J Pathol 1993; 170:145.</a></li><li><a class="nounderline abstract_t">Peters K, Knoll JH, Kadin ME. Cytogenetic findings in regressing skin lesions of lymphomatoid papulosis. Cancer Genet Cytogenet 1995; 80:13.</a></li><li><a class="nounderline abstract_t">Kempf W, Kadin ME, Kutzner H, et al. Lymphomatoid papulosis and human herpesviruses--A PCR-based evaluation for the presence of human herpesvirus 6, 7 and 8 related herpesviruses. J Cutan Pathol 2001; 28:29.</a></li><li><a class="nounderline abstract_t">Kempf W, Kadin ME, Dvorak AM, et al. Endogenous retroviral elements, but not exogenous retroviruses, are detected in CD30-positive lymphoproliferative disorders of the skin. Carcinogenesis 2003; 24:301.</a></li><li><a class="nounderline abstract_t">Ponti R, Bergallo M, Costa C, et al. Human herpesvirus 7 detection by quantitative real time polymerase chain reaction in primary cutaneous T-cell lymphomas and healthy subjects: lack of a pathogenic role. Br J Dermatol 2008; 159:1131.</a></li><li><a class="nounderline abstract_t">Kadin ME, Hamilton RG, Vonderheid EC. Evidence linking atopy and staphylococcal superantigens to the pathogenesis of lymphomatoid papulosis, a recurrent CD30+ cutaneous lymphoproliferative disorder. PLoS One 2020; 15:e0228751.</a></li><li><a class="nounderline abstract_t">Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8:11.</a></li><li><a class="nounderline abstract_t">Wright CW, Duckett CS. The aryl hydrocarbon nuclear translocator alters CD30-mediated NF-kappaB-dependent transcription. Science 2009; 323:251.</a></li><li><a class="nounderline abstract_t">Hirsch B, Hummel M, Bentink S, et al. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol 2008; 172:510.</a></li><li><a class="nounderline abstract_t">Franchina M, Kadin ME, Abraham LJ. Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders. Cancer Epidemiol Biomarkers Prev 2005; 14:1322.</a></li><li><a class="nounderline abstract_t">Steinhoff M, Hummel M, Anagnostopoulos I, et al. Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common clonal T-cell origin. Blood 2002; 100:578.</a></li><li><a class="nounderline abstract_t">Humme D, Lukowsky A, Steinhoff M, et al. Dominance of nonmalignant T-cell clones and distortion of the TCR repertoire in the peripheral blood of patients with cutaneous CD30+ lymphoproliferative disorders. J Invest Dermatol 2009; 129:89.</a></li><li><a class="nounderline abstract_t">Weiss LM, Wood GS, Trela M, et al. Clonal T-cell populations in lymphomatoid papulosis. Evidence of a lymphoproliferative origin for a clinically benign disease. N Engl J Med 1986; 315:475.</a></li><li><a class="nounderline abstract_t">Schultz JC, Granados S, Vonderheid EC, Hwang ST. T-cell clonality of peripheral blood lymphocytes in patients with lymphomatoid papulosis. J Am Acad Dermatol 2005; 53:152.</a></li><li><a class="nounderline abstract_t">Miquel J, Fraitag S, Hamel-Teillac D, et al. Lymphomatoid papulosis in children: a series of 25 cases. Br J Dermatol 2014; 171:1138.</a></li><li><a class="nounderline abstract_t">Davis TH, Morton CC, Miller-Cassman R, et al. Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. N Engl J Med 1992; 326:1115.</a></li><li><a class="nounderline abstract_t">Chott A, Vonderheid EC, Olbricht S, et al. The dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis. J Invest Dermatol 1996; 106:696.</a></li><li><a class="nounderline abstract_t">Amagai M, Kawakubo Y, Tsuyuki A, Harada R. Lymphomatoid papulosis followed by Ki-1 positive anaplastic large cell lymphoma: proliferation of a common T-cell clone. J Dermatol 1995; 22:743.</a></li><li><a class="nounderline abstract_t">Assaf C, Hummel M, Dippel E, et al. Common clonal T-cell origin in a patient with T-prolymphocytic leukaemia and associated cutaneous T-cell lymphomas. Br J Haematol 2003; 120:488.</a></li><li><a class="nounderline abstract_t">Zackheim HS, Jones C, Leboit PE, et al. Lymphomatoid papulosis associated with mycosis fungoides: a study of 21 patients including analyses for clonality. J Am Acad Dermatol 2003; 49:620.</a></li><li><a class="nounderline abstract_t">Basarab T, Fraser-Andrews EA, Orchard G, et al. Lymphomatoid papulosis in association with mycosis fungoides: a study of 15 cases. Br J Dermatol 1998; 139:630.</a></li><li><a class="nounderline abstract_t">Volkenandt M, Bertino JR, Shenoy BV, et al. Molecular evidence for a clonal relationship between lymphomatoid papulosis and Ki-1 positive large cell anaplastic lymphoma. J Dermatol Sci 1993; 6:121.</a></li><li><a class="nounderline abstract_t">Wood GS, Crooks CF, Uluer AZ. Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin. J Invest Dermatol 1995; 105:51.</a></li><li><a class="nounderline abstract_t">Gallardo F, Costa C, Bellosillo B, et al. Lymphomatoid papulosis associated with mycosis fungoides: clinicopathological and molecular studies of 12 cases. Acta Derm Venereol 2004; 84:463.</a></li><li><a class="nounderline abstract_t">Kadin ME, Cavaille-Coll MW, Gertz R, et al. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc Natl Acad Sci U S A 1994; 91:6002.</a></li><li><a class="nounderline abstract_t">Schiemann WP, Pfeifer WM, Levi E, et al. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood 1999; 94:2854.</a></li><li><a class="nounderline abstract_t">Willemze R, Meyer CJ, Van Vloten WA, Scheffer E. The clinical and histological spectrum of lymphomatoid papulosis. Br J Dermatol 1982; 107:131.</a></li><li><a class="nounderline abstract_t">DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996; 87:3437.</a></li><li><a class="nounderline abstract_t">Mathas S, Kreher S, Meaburn KJ, et al. Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma. Proc Natl Acad Sci U S A 2009; 106:5831.</a></li><li><a class="nounderline abstract_t">Velusamy T, Kiel MJ, Sahasrabuddhe AA, et al. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood 2014; 124:3768.</a></li><li><a class="nounderline abstract_t">Braun FK, Hirsch B, Al-Yacoub N, et al. Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP. J Invest Dermatol 2010; 130:826.</a></li><li><a class="nounderline abstract_t">Kikuchi A, Nishikawa T. Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases. Arch Dermatol 1997; 133:829.</a></li><li><a class="nounderline abstract_t">Greisser J, Doebbeling U, Roos M, et al. Apoptosis in CD30-positive lymphoproliferative disorders of the skin. Exp Dermatol 2005; 14:380.</a></li><li><a class="nounderline abstract_t">Paulli M, Berti E, Boveri E, et al. Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily. Hum Pathol 1998; 29:1223.</a></li><li><a class="nounderline abstract_t">Nevala H, Karenko L, Vakeva L, Ranki A. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis. Br J Dermatol 2001; 145:928.</a></li><li><a class="nounderline abstract_t">Saggini A, Gulia A, Argenyi Z, et al. A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases. Am J Surg Pathol 2010; 34:1168.</a></li><li><a class="nounderline abstract_t">Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999; 155:483.</a></li><li><a class="nounderline abstract_t">Kempf W, Kazakov DV, Schärer L, et al. Angioinvasive lymphomatoid papulosis: a new variant simulating aggressive lymphomas. Am J Surg Pathol 2013; 37:1.</a></li><li><a class="nounderline abstract_t">Kempf W, Kazakov DV, Baumgartner HP, Kutzner H. Follicular lymphomatoid papulosis revisited: a study of 11 cases, with new histopathological findings. J Am Acad Dermatol 2013; 68:809.</a></li><li><a class="nounderline abstract_t">Crowson AN, Baschinsky DY, Kovatich A, Magro C. Granulomatous eccrinotropic lymphomatoid papulosis. Am J Clin Pathol 2003; 119:731.</a></li><li><a class="nounderline abstract_t">Kadin M, Nasu K, Sako D, et al. Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin's disease-associated antigens. Am J Pathol 1985; 119:315.</a></li><li><a class="nounderline abstract_t">Kummer JA, Vermeer MH, Dukers D, et al. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol 1997; 109:636.</a></li><li><a class="nounderline abstract_t">Wang Y, Gu X, Zhang G, et al. SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21. Blood 2014; 123:3452.</a></li><li><a class="nounderline abstract_t">Sun J, Yi S, Qiu L, et al. SATB1 Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile. J Invest Dermatol 2018; 138:1795.</a></li><li><a class="nounderline abstract_t">Nijsten T, Curiel-Lewandrowski C, Kadin ME. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Arch Dermatol 2004; 140:306.</a></li><li><a class="nounderline abstract_t">Kempf W. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol 2006; 33 Suppl 1:58.</a></li><li><a class="nounderline abstract_t">Sharaf MA, Romanelli P, Kirsner R, Miteva M. Angioinvasive lymphomatoid papulosis: another case of a newly described variant. Am J Dermatopathol 2014; 36:e75.</a></li><li><a class="nounderline abstract_t">Chimenti S, Fargnoli MC, Pacifico A, Peris K. Mucosal involvement in a patient with lymphomatoid papulosis. J Am Acad Dermatol 2001; 44:339.</a></li><li><a class="nounderline abstract_t">Kato N, Tomita Y, Yoshida K, Hisai H. Involvement of the tongue by lymphomatoid papulosis. Am J Dermatopathol 1998; 20:522.</a></li><li><a class="nounderline abstract_t">Benslama L, Andre CV, Charlotte F, et al. [Mucosal lymphomatoid papulosis: 2 cases]. Rev Stomatol Chir Maxillofac Chir Orale 2015; 116:111.</a></li><li><a class="nounderline abstract_t">Heald P, Subtil A, Breneman D, Wilson LD. Persistent agmination of lymphomatoid papulosis: an equivalent of limited plaque mycosis fungoides type of cutaneous T-cell lymphoma. J Am Acad Dermatol 2007; 57:1005.</a></li><li><a class="nounderline abstract_t">Torrelo A, Colmenero I, Hernández A, Goiriz R. Persistent agmination of lymphomatoid papulosis. Pediatr Dermatol 2009; 26:762.</a></li><li><a class="nounderline abstract_t">Hsu YJ, Su LH, Hsu YL, et al. Localized lymphomatoid papulosis. J Am Acad Dermatol 2010; 62:353.</a></li><li><a class="nounderline abstract_t">González-López MA, González-Vela Mdel C, Caballero C, et al. Localized lymphomatoid papulosis. Int J Dermatol 2015; 54:e98.</a></li><li><a class="nounderline abstract_t">Chaudhari PR, Emanuel P, Levitt J. Type B follicular lymphomatoid papulosis. Cutis 2010; 85:307.</a></li><li><a class="nounderline abstract_t">Kato N, Matsue K. Follicular lymphomatoid papulosis. Am J Dermatopathol 1997; 19:189.</a></li><li><a class="nounderline abstract_t">Deroo-Berger MC, Skowron F, Ronger S, et al. Lymphomatoid papulosis: a localized form with acral pustular involvement. Dermatology 2002; 205:60.</a></li><li><a class="nounderline abstract_t">Barnadas MA, López D, Pujol RM, et al. Pustular lymphomatoid papulosis in childhood. J Am Acad Dermatol 1992; 27:627.</a></li><li><a class="nounderline abstract_t">Wang HH, Myers T, Lach LJ, et al. Increased risk of lymphoid and nonlymphoid malignancies in patients with lymphomatoid papulosis. Cancer 1999; 86:1240.</a></li><li><a class="nounderline abstract_t">Melchers RC, Willemze R, Bekkenk MW, et al. Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis. J Eur Acad Dermatol Venereol 2020; 34:260.</a></li><li><a class="nounderline abstract_t">Wieser I, Oh CW, Talpur R, Duvic M. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol 2016; 74:59.</a></li><li><a class="nounderline abstract_t">Eberle FC, Song JY, Xi L, et al. Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma. Am J Surg Pathol 2012; 36:716.</a></li><li><a class="nounderline abstract_t">Gniadecki R, Lukowsky A, Rossen K, et al. Bone marrow precursor of extranodal T-cell lymphoma. Blood 2003; 102:3797.</a></li><li><a class="nounderline abstract_t">Knaus PI, Lindemann D, DeCoteau JF, et al. A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol Cell Biol 1996; 16:3480.</a></li><li><a class="nounderline abstract_t">Cordel N, Tressières B, D'Incan M, et al. Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis. Oncologist 2016; 21:76.</a></li><li><a class="nounderline abstract_t">de Souza A, el-Azhary RA, Camilleri MJ, et al. In search of prognostic indicators for lymphomatoid papulosis: a retrospective study of 123 patients. J Am Acad Dermatol 2012; 66:928.</a></li><li><a class="nounderline abstract_t">Kempf W, Levi E, Kamarashev J, et al. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. J Cutan Pathol 2002; 29:295.</a></li><li><a class="nounderline abstract_t">Kadin ME, Pavlov IY, Delgado JC, Vonderheid EC. High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides. J Invest Dermatol 2012; 132:703.</a></li><li><a class="nounderline abstract_t">Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118:4024.</a></li><li><a class="nounderline abstract_t">Pulitzer M, Ogunrinade O, Lin O, Steinherz P. ALK-positive (2p23 rearranged) anaplastic large cell lymphoma with localization to the skin in a pediatric patient. J Cutan Pathol 2015; 42:182.</a></li><li><a class="nounderline abstract_t">Sasaki K, Sugaya M, Fujita H, et al. A case of primary cutaneous anaplastic large cell lymphoma with variant anaplastic lymphoma kinase translocation. Br J Dermatol 2004; 150:1202.</a></li><li><a class="nounderline abstract_t">Kadin ME, Pinkus JL, Pinkus GS, et al. Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. Am J Surg Pathol 2008; 32:1421.</a></li><li><a class="nounderline abstract_t">Xue D, Li X, Ren Y, et al. Primary Cutaneous Anaplastic Large Cell Lymphoma With Positive ALK Expression and a Rapidly Progressive Cutaneous Nodule. Int J Surg Pathol 2015; 23:333.</a></li><li><a class="nounderline abstract_t">ten Berge RL, Snijdewint FG, von Mensdorff-Pouilly S, et al. MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form. J Clin Pathol 2001; 54:933.</a></li><li><a class="nounderline abstract_t">Yang S, Khera P, Wahlgren C, et al. Cutaneous anaplastic large-cell lymphoma should be evaluated for systemic involvement regardless of ALK-1 status: case reports and review of literature. Am J Clin Dermatol 2011; 12:203.</a></li><li><a class="nounderline abstract_t">Su LD, Schnitzer B, Ross CW, et al. The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders. J Cutan Pathol 1997; 24:597.</a></li><li><a class="nounderline abstract_t">Kadin ME, Sako D, Berliner N, et al. Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy. Blood 1986; 68:1042.</a></li><li><a class="nounderline abstract_t">Lamant L, Pileri S, Sabattini E, et al. Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in five cases. Haematologica 2010; 95:449.</a></li><li><a class="nounderline abstract_t">de la Garza Bravo MM, Patel KP, Loghavi S, et al. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Hum Pathol 2015; 46:558.</a></li><li><a class="nounderline abstract_t">Kodama K, Fink-Puches R, Massone C, et al. Papular mycosis fungoides: a new clinical variant of early mycosis fungoides. J Am Acad Dermatol 2005; 52:694.</a></li><li><a class="nounderline abstract_t">Vonderheid EC, Kadin ME, Telang GH. Papular mycosis fungoides: Six new cases and association with chronic lymphocytic leukemia. World J Dermatol 2016; 5:136.</a></li><li><a class="nounderline abstract_t">Rodríguez-Pinilla SM, Ortiz-Romero PL, Monsalvez V, et al. TCR-γ expression in primary cutaneous T-cell lymphomas. Am J Surg Pathol 2013; 37:375.</a></li><li><a class="nounderline abstract_t">Parveen Z, Thompson K. Subcutaneous panniculitis-like T-cell lymphoma: redefinition of diagnostic criteria in the recent World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas. Arch Pathol Lab Med 2009; 133:303.</a></li><li><a class="nounderline abstract_t">Magaña M, Massone C, Magaña P, Cerroni L. Clinicopathologic Features of Hydroa Vacciniforme-Like Lymphoma: A Series of 9 Patients. Am J Dermatopathol 2016; 38:20.</a></li><li><a class="nounderline abstract_t">Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol 2002; 10:7.</a></li><li><a class="nounderline abstract_t">Takata K, Hong ME, Sitthinamsuwan P, et al. Primary cutaneous NK/T-cell lymphoma, nasal type and CD56-positive peripheral T-cell lymphoma: a cellular lineage and clinicopathologic study of 60 patients from Asia. Am J Surg Pathol 2015; 39:1.</a></li><li><a class="nounderline abstract_t">Savage KJ, Ferreri AJ, Zinzani PL, Pileri SA. Peripheral T-cell lymphoma--not otherwise specified. Crit Rev Oncol Hematol 2011; 79:321.</a></li><li><a class="nounderline abstract_t">Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111:5496.</a></li><li><a class="nounderline abstract_t">Geissinger E, Sadler P, Roth S, et al. Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations. Haematologica 2010; 95:1697.</a></li><li><a class="nounderline abstract_t">Werner B, Massone C, Kerl H, Cerroni L. Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin. J Cutan Pathol 2008; 35:1100.</a></li><li><a class="nounderline abstract_t">Kempf W, Kazakov DV, Palmedo G, et al. Pityriasis lichenoides et varioliformis acuta with numerous CD30(+) cells: a variant mimicking lymphomatoid papulosis and other cutaneous lymphomas. A clinicopathologic, immunohistochemical, and molecular biological study of 13 cases. Am J Surg Pathol 2012; 36:1021.</a></li><li><a class="nounderline abstract_t">Dereure O, Levi E, Kadin ME. T-Cell clonality in pityriasis lichenoides et varioliformis acuta: a heteroduplex analysis of 20 cases. Arch Dermatol 2000; 136:1483.</a></li><li><a class="nounderline abstract_t">Jung J, Levin EC, Jarrett R, et al. Lymphomatoid drug reaction to ustekinumab. Arch Dermatol 2011; 147:992.</a></li><li><a class="nounderline abstract_t">Saeed SA, Bazza M, Zaman M, Ryatt KS. Cefuroxime induced lymphomatoid hypersensitivity reaction. Postgrad Med J 2000; 76:577.</a></li><li><a class="nounderline abstract_t">Fukamachi S, Sugita K, Sawada Y, et al. Drug-induced CD30+ T cell pseudolymphoma. Eur J Dermatol 2009; 19:292.</a></li><li><a class="nounderline abstract_t">Nathan DL, Belsito DV. Carbamazepine-induced pseudolymphoma with CD-30 positive cells. J Am Acad Dermatol 1998; 38:806.</a></li><li><a class="nounderline abstract_t">Leinweber B, Kerl H, Cerroni L. Histopathologic features of cutaneous herpes virus infections (herpes simplex, herpes varicella/zoster): a broad spectrum of presentations with common pseudolymphomatous aspects. Am J Surg Pathol 2006; 30:50.</a></li><li><a class="nounderline abstract_t">Oflazoglu E, Simpson EL, Takiguchi R, et al. CD30 expression on CD1a+ and CD8+ cells in atopic dermatitis and correlation with disease severity. Eur J Dermatol 2008; 18:41.</a></li><li><a class="nounderline abstract_t">Lipozencić J, Bobek D, Jakić-Razumović J. The presence of surface CD30 on T cells in atopic dermatitis. Acta Dermatovenerol Croat 2003; 11:145.</a></li><li><a class="nounderline abstract_t">Cavagni G, Caffarelli C, Facchetti F, et al. Cutaneous CD30+ cells in children with atopic dermatitis. Int Arch Allergy Immunol 2000; 121:224.</a></li><li><a class="nounderline abstract_t">Dummer W, Rose C, Bröcker EB. Expression of CD30 on T helper cells in the inflammatory infiltrate of acute atopic dermatitis but not of allergic contact dermatitis. Arch Dermatol Res 1998; 290:598.</a></li><li><a class="nounderline abstract_t">Massi D, Trotta M, Franchi A, et al. Atypical CD30+ cutaneous lymphoid proliferation in a patient with tuberculosis infection. Am J Dermatopathol 2004; 26:234.</a></li><li><a class="nounderline abstract_t">Kadin ME. Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders. Oncology (Williston Park) 2009; 23:1158.</a></li><li><a class="nounderline abstract_t">Zelenetz AD. Guidelines for NHL: updates to the management of diffuse large B-cell lymphoma and new guidelines for primary cutaneous CD30+ T-cell lymphoproliferative disorders and T-cell large granular lymphocytic leukemia. J Natl Compr Canc Netw 2014; 12:797.</a></li><li><a class="nounderline abstract_t">Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996; 34:470.</a></li><li><a class="nounderline abstract_t">Bruijn MS, Horváth B, van Voorst Vader PC, et al. Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group. Br J Dermatol 2015; 173:1319.</a></li><li><a class="nounderline abstract_t">Newland KM, McCormack CJ, Twigger R, et al. The efficacy of methotrexate for lymphomatoid papulosis. J Am Acad Dermatol 2015; 72:1088.</a></li><li><a class="nounderline abstract_t">Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther 2007; 20:216.</a></li><li><a class="nounderline abstract_t">Shen S, O'Brien T, Yap LM, et al. The use of methotrexate in dermatology: a review. Australas J Dermatol 2012; 53:1.</a></li><li><a class="nounderline abstract_t">Volkenandt M, Kerscher M, Sander C, et al. PUVA-bath photochemotherapy resulting in rapid clearance of lymphomatoid papulosis in a child. Arch Dermatol 1995; 131:1094.</a></li><li><a class="nounderline abstract_t">Hoetzenecker W, Guenova E, Hoetzenecker K, et al. Successful treatment of recalcitrant lymphomatoid papulosis in a child with PUVA-bath photochemotherapy. Eur J Dermatol 2009; 19:646.</a></li><li><a class="nounderline abstract_t">Errichetti E, Piccirillo A, Ricciuti F, Ricciuti F. Steroid-Resistant Localized Lymphomatoid Papulosis Treated with Local Bath-PUVA Therapy. Indian J Dermatol 2013; 58:163.</a></li><li><a class="nounderline abstract_t">Calzavara-Pinton P, Venturini M, Sala R. Medium-dose UVA1 therapy of lymphomatoid papulosis. J Am Acad Dermatol 2005; 52:530.</a></li><li><a class="nounderline abstract_t">Sanchez NP, Pittelkow MR, Muller SA, et al. The clinicopathologic spectrum of lymphomatoid papulosis: study of 31 cases. J Am Acad Dermatol 1983; 8:81.</a></li><li><a class="nounderline abstract_t">Perna AG, Jones DM, Duvic M. Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel. Clin Lymphoma 2004; 5:190.</a></li><li><a class="nounderline abstract_t">Rodrigues M, McCormack C, Yap LM, et al. Successful treatment of lymphomatoid papulosis with photodynamic therapy. Australas J Dermatol 2009; 50:129.</a></li><li><a class="nounderline abstract_t">Kontos AP, Kerr HA, Malick F, et al. 308-nm excimer laser for the treatment of lymphomatoid papulosis and stage IA mycosis fungoides. Photodermatol Photoimmunol Photomed 2006; 22:168.</a></li><li><a class="nounderline abstract_t">Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology 2003; 206:142.</a></li><li><a class="nounderline abstract_t">Zackheim HS, Epstein EH Jr, Crain WR. Topical carmustine therapy for lymphomatoid papulosis. Arch Dermatol 1985; 121:1410.</a></li><li><a class="nounderline abstract_t">Lewis DJ, Talpur R, Huen AO, et al. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results. JAMA Dermatol 2017; 153:1302.</a></li><li><a class="nounderline abstract_t">Duvic M, Tetzlaff MT, Gangar P, et al. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol 2015; 33:3759.</a></li><li><a class="nounderline abstract_t">Van Neer FJ, Toonstra J, Van Voorst Vader PC, et al. Lymphomatoid papulosis in children: a study of 10 children registered by the Dutch Cutaneous Lymphoma Working Group. Br J Dermatol 2001; 144:351.</a></li><li><a class="nounderline abstract_t">Martorell-Calatayud A, Hernández-Martín A, Colmenero I, et al. [Lymphomatoid papulosis in children: report of 9 cases and review of the literature]. Actas Dermosifiliogr 2010; 101:693.</a></li><li><a class="nounderline abstract_t">de Souza A, Camilleri MJ, Wada DA, et al. Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients. J Am Acad Dermatol 2009; 61:993.</a></li><li><a class="nounderline abstract_t">Yip L, Darling S, Orchard D. Lymphomatoid papulosis in children: experience of five cases and the treatment efficacy of methotrexate. Australas J Dermatol 2011; 52:279.</a></li><li><a class="nounderline abstract_t">Fernández-de-Misa R, Hernández-Machín B, Servitje O, et al. First-line treatment in lymphomatoid papulosis: a retrospective multicentre study. Clin Exp Dermatol 2018; 43:137.</a></li></ol></div><div id="topicVersionRevision">Topic 15725 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5634442" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign--histologically malignant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15692063" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : WHO-EORTC classification for cutaneous lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14710887" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Primary cutaneous CD30-positive lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10845893" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17659039" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cutaneous lymphomas in Germany: an analysis of the Central Cutaneous Lymphoma Registry of the German Society of Dermatology (DDG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19196298" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19196298" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23648461" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8393923" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Absence of Epstein-Barr viral RNA in lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7697626" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cytogenetic findings in regressing skin lesions of lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11168749" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lymphomatoid papulosis and human herpesviruses--A PCR-based evaluation for the presence of human herpesvirus 6, 7 and 8 related herpesviruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12584181" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Endogenous retroviral elements, but not exogenous retroviruses, are detected in CD30-positive lymphoproliferative disorders of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18782321" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Human herpesvirus 7 detection by quantitative real time polymerase chain reaction in primary cutaneous T-cell lymphomas and healthy subjects: lack of a pathogenic role.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32049976" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Evidence linking atopy and staphylococcal superantigens to the pathogenesis of lymphomatoid papulosis, a recurrent CD30+ cutaneous lymphoproliferative disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18097461" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The anaplastic lymphoma kinase in the pathogenesis of cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19131627" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The aryl hydrocarbon nuclear translocator alters CD30-mediated NF-kappaB-dependent transcription.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18187570" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894695" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12091351" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common clonal T-cell origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18633437" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dominance of nonmalignant T-cell clones and distortion of the TCR repertoire in the peripheral blood of patients with cutaneous CD30+ lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3488502" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clonal T-cell populations in lymphomatoid papulosis. Evidence of a lymphoproliferative origin for a clinically benign disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15965440" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : T-cell clonality of peripheral blood lymphocytes in patients with lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24749749" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Lymphomatoid papulosis in children: a series of 25 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1532439" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618007" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8586753" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Lymphomatoid papulosis followed by Ki-1 positive anaplastic large cell lymphoma: proliferation of a common T-cell clone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12580966" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Common clonal T-cell origin in a patient with T-prolymphocytic leukaemia and associated cutaneous T-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512906" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Lymphomatoid papulosis associated with mycosis fungoides: a study of 21 patients including analyses for clonality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10025972" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Lymphomatoid papulosis in association with mycosis fungoides: a study of 15 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8274457" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Molecular evidence for a clonal relationship between lymphomatoid papulosis and Ki-1 positive large cell anaplastic lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7615976" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Lymphomatoid papulosis and associated cutaneous lymphoproliferative disorders exhibit a common clonal origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15844638" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Lymphomatoid papulosis associated with mycosis fungoides: clinicopathological and molecular studies of 12 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8016105" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Loss of receptors for transforming growth factor beta in human T-cell malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10515889" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7104214" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The clinical and histological spectrum of lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8605362" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19321746" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25349176" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19890350" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Resistance of cutaneous anaplastic large-cell lymphoma cells to apoptosis by death ligands is enhanced by CD30-mediated overexpression of c-FLIP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9236520" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Apoptotic and proliferating cells in cutaneous lymphoproliferative diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15854132" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Apoptosis in CD30-positive lymphoproliferative disorders of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9824099" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cutaneous CD30+ lymphoproliferative disorders: expression of bcl-2 and proteins of the tumor necrosis factor receptor superfamily.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11899146" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20661014" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10433941" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23026936" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Angioinvasive lymphomatoid papulosis: a new variant simulating aggressive lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23375516" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Follicular lymphomatoid papulosis revisited: a study of 11 cases, with new histopathological findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12760293" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Granulomatous eccrinotropic lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3158209" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin's disease-associated antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9347791" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24747435" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29510190" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : SATB1 Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15023774" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16412214" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23863551" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Angioinvasive lymphomatoid papulosis: another case of a newly described variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11174410" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Mucosal involvement in a patient with lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9790120" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Involvement of the tongue by lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25800967" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : [Mucosal lymphomatoid papulosis: 2 cases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919773" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Persistent agmination of lymphomatoid papulosis: an equivalent of limited plaque mycosis fungoides type of cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20199467" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Persistent agmination of lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20115961" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Localized lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25556677" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Localized lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20666192" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Type B follicular lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9129706" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Follicular lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12145437" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Lymphomatoid papulosis: a localized form with acral pustular involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1401319" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pustular lymphomatoid papulosis in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10506709" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Increased risk of lymphoid and nonlymphoid malignancies in patients with lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31715046" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26518172" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22367293" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12842987" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Bone marrow precursor of extranodal T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8668164" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A dominant inhibitory mutant of the type II transforming growth factor beta receptor in the malignant progression of a cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26668250" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21982062" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : In search of prognostic indicators for lymphomatoid papulosis: a retrospective study of 123 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100631" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Fascin expression in CD30-positive cutaneous lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22071475" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : High soluble CD30, CD25, and IL-6 may identify patients with worse survival in CD30+ cutaneous lymphomas and early mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21841159" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25404214" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : ALK-positive (2p23 rearranged) anaplastic large cell lymphoma with localization to the skin in a pediatric patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15214912" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A case of primary cutaneous anaplastic large cell lymphoma with variant anaplastic lymphoma kinase translocation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18670345" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25633507" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Primary Cutaneous Anaplastic Large Cell Lymphoma With Positive ALK Expression and a Rapidly Progressive Cutaneous Nodule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11729213" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : MUC1 (EMA) is preferentially expressed by ALK positive anaplastic large cell lymphoma, in the normally glycosylated or only partly hypoglycosylated form.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21366363" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Cutaneous anaplastic large-cell lymphoma should be evaluated for systemic involvement regardless of ALK-1 status: case reports and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9449486" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The t(2;5)-associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3490284" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19951975" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cutaneous presentation of ALK-positive anaplastic large cell lymphoma following insect bites: evidence for an association in five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25666664" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15793526" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Papular mycosis fungoides: a new clinical variant of early mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Papular mycosis fungoides: Six new cases and association with chronic lymphocytic leukemia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23348211" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : TCR-γexpression in primary cutaneous T-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19195975" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Subcutaneous panniculitis-like T-cell lymphoma: redefinition of diagnostic criteria in the recent World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26368647" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Clinicopathologic Features of Hydroa Vacciniforme-Like Lymphoma: A Series of 9 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11893040" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25188863" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Primary cutaneous NK/T-cell lymphoma, nasal type and CD56-positive peripheral T-cell lymphoma: a cellular lineage and clinicopathologic study of 60 patients from Asia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20702104" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Peripheral T-cell lymphoma--not otherwise specified.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18385450" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20511667" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18616762" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22472952" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pityriasis lichenoides et varioliformis acuta with numerous CD30(+) cells: a variant mimicking lymphomatoid papulosis and other cutaneous lymphomas. A clinicopathologic, immunohistochemical, and molecular biological study of 13 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11115158" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : T-Cell clonality in pityriasis lichenoides et varioliformis acuta: a heteroduplex analysis of 20 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844471" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Lymphomatoid drug reaction to ustekinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10964126" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Cefuroxime induced lymphomatoid hypersensitivity reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19336342" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Drug-induced CD30+ T cell pseudolymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9591791" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Carbamazepine-induced pseudolymphoma with CD-30 positive cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16330942" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Histopathologic features of cutaneous herpes virus infections (herpes simplex, herpes varicella/zoster): a broad spectrum of presentations with common pseudolymphomatous aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18086588" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : CD30 expression on CD1a+ and CD8+ cells in atopic dermatitis and correlation with disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12967506" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The presence of surface CD30 on T cells in atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10729781" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Cutaneous CD30+ cells in children with atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9860279" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Expression of CD30 on T helper cells in the inflammatory infiltrate of acute atopic dermatitis but not of allergic contact dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15166514" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Atypical CD30+ cutaneous lymphoid proliferation in a patient with tuberculosis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20043465" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24853220" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Guidelines for NHL: updates to the management of diffuse large B-cell lymphoma and new guidelines for primary cutaneous CD30+ T-cell lymphoproliferative disorders and T-cell large granular lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8609262" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25998985" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Recommendations for treatment of lymphomatoid papulosis with methotrexate: a report from the Dutch Cutaneous Lymphoma Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25981010" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The efficacy of methotrexate for lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17970887" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Methotrexate in dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22309324" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : The use of methotrexate in dermatology: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7661623" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : PUVA-bath photochemotherapy resulting in rapid clearance of lymphomatoid papulosis in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797036" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Successful treatment of recalcitrant lymphomatoid papulosis in a child with PUVA-bath photochemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23716855" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Steroid-Resistant Localized Lymphomatoid Papulosis Treated with Local Bath-PUVA Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15761440" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Medium-dose UVA1 therapy of lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6826811" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : The clinicopathologic spectrum of lymphomatoid papulosis: study of 31 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15636695" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19397568" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Successful treatment of lymphomatoid papulosis with photodynamic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16719874" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : 308-nm excimer laser for the treatment of lymphomatoid papulosis and stage IA mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12592082" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Bexarotene is a new treatment option for lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4051529" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Topical carmustine therapy for lymphomatoid papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28980004" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26261247" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11251571" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Lymphomatoid papulosis in children: a study of 10 children registered by the Dutch Cutaneous Lymphoma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20965012" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : [Lymphomatoid papulosis in children: report of 9 cases and review of the literature].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19577330" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Clinical, histopathologic, and immunophenotypic features of lymphomatoid papulosis with CD8 predominance in 14 pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22070703" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Lymphomatoid papulosis in children: experience of five cases and the treatment efficacy of methotrexate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28994134" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : First-line treatment in lymphomatoid papulosis: a retrospective multicentre study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
